Women's health study finds vitamin E does not protect women from heart attack, stroke, or cancer

July 05, 2005

Vitamin E supplements do not protect healthy women against heart attacks and stroke, according to new results from the Women's Health Study, a long-term clinical trial of the effect of vitamin E and aspirin on both the prevention of cardiovascular disease and of cancer.

The vitamin E results of the Women's Health Study are published in the July 6 issue of the Journal of the American Medical Association. In addition to the cardiovascular disease findings, the study authors report that there was no effect of vitamin E on total cancer or on the most common cancers in women - breast, lung, and colon cancers. The Women's Health Study was funded by the National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute of the National Institutes of Health.

"This landmark trial has given women and their physicians important health information. We can now say that despite their initial promise, vitamin E supplements do not prevent heart attack and stroke. Instead, women should focus on well proven means of heart disease prevention, including leading a healthy lifestyle and controlling risk factors such as high blood pressure and high cholesterol," said NHLBI Director Elizabeth G. Nabel, M.D.

The Women's Health Study was conducted between 1992 and 2004. The participants were 39,876 healthy women age 45 years and older who were randomly assigned to receive 600 IU of Vitamin E or placebo and low-dose aspirin or placebo on alternate days. The participants were followed for an average of 10.1 years. The aspirin results published last March found no benefit of aspirin (100 mg every other day) in preventing first heart attacks or death from cardiovascular causes in women but did find a reduced risk of stroke overall, as well as reduced risk of both stroke and heart attack in women aged 65 and older.

In recent years, there has been a great deal of public and scientific interest in the potential of antioxidant vitamins like vitamin E to reduce the risk of cardiovascular disease. Laboratory and animal research suggested that vitamin E might prevent the accumulation of fatty deposits inside arteries, which would reduce the chance of clogged and blocked arteries. Other large observational studies have also suggested that people who eat foods high in vitamin E or take supplements have a lower risk of coronary heart disease. Although several clinical trials conducted prior to the Women's Health study found little cardiovascular benefit from vitamin E, these trials were shorter and primarily studied individuals with cardiovascular disease or CVD risk factors. The intent of the Women's Health Study was to provide a long-term look at the effects of vitamin E supplementation among healthy women.

Participants in the Women's Health Study were monitored for major cardiovascular "events" - a combination of nonfatal heart attack, nonfatal stroke, or cardiovascular death. By the end of the study, participants in the vitamin E group had 482 such events compared to 517 in the placebo group. However, this difference was not statistically different.

For the individual cardiovascular events, the study findings were:

  • Nonfatal heart attacks: 184 in the vitamin E group versus 181 in the placebo group - not a statistically significant difference.

  • Nonfatal strokes: 220 in the vitamin E group versus 222 in the placebo group - not statistically significant.

    Study investigators also found no significant effect of vitamin E on total deaths (deaths from all causes). By the end of the study, there were 636 deaths in the vitamin E group compared to 615 in the placebo group.

    Although total deaths were unaffected by vitamin E, there was a significant 24 percent reduction in cardiovascular deaths among all women taking the vitamin (106 deaths in the vitamin E group versus 140 in the placebo group). In another positive finding, women 65 and older taking vitamin E had a 26 percent decrease in heart attacks and cardiovascular deaths, but not strokes.

    "These intriguing findings deserve further study. But they were not part of the primary aim of the study - to look at the effect of vitamin E on overall cardiovascular disease, which includes heart attack, stroke, and cardiovascular death. Additionally, previous studies of vitamin E in patients with heart disease have not shown any benefit for cardiovascular deaths. At present, we cannot recommend vitamin E for prevention against cardiovascular disease or cancer," said lead investigator I-Min Lee, MBBS, ScD of Brigham and Women's Hospital.

    The study finding of a decrease in major cardiovascular events among women age 65 years and older is relatively unique, added Dr. Lee. "Almost all previous trials have not reported findings by age. If other current trials provide age-related results, these additional data will help clarify the Women's Health Study results of benefit among the women aged 65 years and older," she said.

    Overall, the results were not affected by a study participant's menopausal status, use of hormone therapy, body mass index, alcohol intake, or physical activity. The study found no significant side effects among women taking vitamin E except for an increase in nosebleeds, which was likely due to chance, as there was no increase in risk of other types of bleeding, including hemorrhagic stroke.

    According to the 1999-2000 National Health and Nutrition Examination Survey, an estimated 13.5 percent of women in the U.S. take vitamin E supplements, although it is not known how many are taking the vitamin to prevent heart disease and stroke.
    NHLBI's Dr. Nabel encouraged women to learn more about proven ways to prevent heart disease, the number one killer of women. The Heart Truth (www.hearttruth.gov.), NHLBI's program to increase women's awareness of the dangers of heart disease, offers resources and information on leading a healthy lifestyle.

    To interview an NHLBI spokesperson about the Women's Health Study findings, contact the NHLBI Communications Office at (301) 496-4236. To interview a study investigator, contact Melanie Franco or Lori Shanks at Brigham and Women's Hospital at (617) 534-1600.

    NHLBI is part of the National Institutes of Health (NIH), the Federal Government's primary agency for biomedical and behavioral research. NIH is a component of the U.S. Department of Health and Human Services. NHLBI press releases and other materials including information about high blood pressure and heart disease are available online at www.nhlbi.nih.gov.

    NIH/National Heart, Lung and Blood Institute

    Related Cancer Articles from Brightsurf:

    New blood cancer treatment works by selectively interfering with cancer cell signalling
    University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

    UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
    A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

    Breast cancer treatment costs highest among young women with metastic cancer
    In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

    Cancer mortality continues steady decline, driven by progress against lung cancer
    The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

    Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
    Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

    Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
    The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

    Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
    Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

    More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
    An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

    New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
    Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

    American Cancer Society outlines blueprint for cancer control in the 21st century
    The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

    Read More: Cancer News and Cancer Current Events
  • Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.